SalvaRx announced that the first patient has been dosed with INT230-6 as part of a Phase 1/2 international clinical study.  Dr. Ian B. Walters, Chief Executive of SalvaRx, has helped design the study and oversaw the medical aspects of INT230-6 as Chief Medical Officer of Intensity. Initiation of the study followed acceptance of an investigational new drug (IND) submission made by Intensity to the U.S. Food and Drug Administration's Division of Oncology Products 1 (DOP1) and receipt from Health Canada of a No Objection Letter. The clinical trial, IT-01 (NCT#03058289), entitled A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers aims to enroll approximately 60 patients with several different types of advanced solid tumors. Intensity's Phase 1/2 study will first assess the safety of INT230-6. Initial tumor types treated will be those at the skin surface (e.g. breast, melanoma, head-and-neck and lymphoma). Subsequent patients receiving INT230-6 will include those with deep tumors (e.g. liver, pancreatic, colon, lung cancers, and others). Investigators will utilize image guidance to inject the tumors. A cohort is planned to study INT230-6 in combination with anti-PD1 agents. The study's primary goal is to demonstrate the safety of INT230-6. Secondary analyses will examine the efficacy of INT230-6 treatment via multiple parameters. The trial includes several adaptive components that will allow for adjustments in patient groups, dosing schedule and dose volumes administered.